Overview: Thrombin Time TestIntroduction: The Thrombin Time Test measures thrombin time to diagnose clotting disorders, causing excessive bleeding. Aligned with 2023 ISTH guidelines, it uses coagulation methods for high specificity, supporting coagulation screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in hematology for patients with suspected clotting disorders.
Other Names: Thrombin Clotting Time Assay, TT Test.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic accuracy.
Historical Milestone: Thrombin time testing began in the 1950s with coagulation research. Methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures thrombin time to diagnose clotting disorders, guides treatment, and evaluates patients with excessive bleeding.
Test Parameters: 1. Thrombin Time 2. Clotting Activity
Pretest Condition: No fasting required. Collect citrated plasma. Report history of bleeding or clotting disorders.
Specimen: Citrated Plasma (NaCit, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document excessive bleeding, bruising, or history of clotting disorders. Include current medications, especially anticoagulants.
Consent: Written consent required, detailing the tests purpose, clotting disorder implications, and risks of sample collection.
Procedural Considerations: Uses automated coagulometers to measure thrombin-induced clotting time. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for clotting disorder diagnosis.
Factors Affecting Result Accuracy: Improper plasma collection or anticoagulant use can affect results. Sample quality impacts sensitivity.
Clinical Significance: Prolonged thrombin time confirms clotting disorders, guiding anticoagulant therapy or factor replacement. Normal results may require PT/PTT testing.
Specialist Consultation: Consult a hematologist for result interpretation and treatment planning.
Additional Supporting Tests: PT, PTT, or fibrinogen levels to confirm clotting disorder diagnosis.
Test Limitations: Non-specific for certain clotting disorders; clinical correlation is needed. Sample quality affects sensitivity.
References: ISTH Coagulation Guidelines, 2023; Journal of Thrombosis and Haemostasis, Di Minno G, 2022.
